Mesoporous Silica Nanoparticles Co-loaded with Lysozyme and Vancomycin for Synergistic Antimicrobial Action

Overview

Journal Sci Rep

Specialty Science

Date 2024 Nov 25

PMID 39587211

Authors

Nasrin Namdar

Bahar Nayeri Fasaei

Parvin Shariati

Seyed Mehdi Joghataei

Ayyoob Arpanaei

Affiliations

Soon will be listed here.

Abstract

Nanotechnology offers a novel strategy for enhancing the susceptibility of pathogens resistant to traditional antibiotics. Another effective strategy is combination therapy, where multiple agents are used together to improve treatment efficacy. In this study, both nanoparticle-based formulation and combinatorial therapy were utilized to develop a potent antibacterial system targeting infectious bacteria. Lysozyme (Lys) and Vancomycin (Van) were co-loaded onto mesoporous silica nanoparticles (MSNs), forming Lys-Van-MSNs. The antimicrobial activity of these nanoparticles was evaluated by determining the minimum inhibitory concentration (MIC) against Staphylococcus aureus. The MIC values for Lys-Van-MSNs were 0.85 µg/ml for Van and 0.168 mg/ml for Lys, reflecting reductions of 86.4% and 93.7%, respectively, compared to the free forms. Additionally, cytotoxicity was tested using MTT, ROS, and hemolysis assays on human cell lines (breast, fibroblast, and AGS), showing over 80% cell viability, indicating minimal toxicity. The MSN-based formulation, with its synergistic antibacterial effects, reduced drug dosage, and high biocompatibility, offers a practical and effective solution for addressing bacterial infections.

References

Behzadi F, Darouie S, Alavi S, Shariati P, Singh G, Dolatshahi-Pirouz A . Stability and Antimicrobial Activity of Nisin-Loaded Mesoporous Silica Nanoparticles: A Game-Changer in the War against Maleficent Microbes. J Agric Food Chem. 2018; 66(16):4233-4243. DOI: 10.1021/acs.jafc.7b05492. View

Ugalde-Arbizu M, Aguilera-Correa J, San Sebastian E, Paez P, Nogales E, Esteban J . Antibacterial Properties of Mesoporous Silica Nanoparticles Modified with Fluoroquinolones and Copper or Silver Species. Pharmaceuticals (Basel). 2023; 16(7). PMC: 10386262. DOI: 10.3390/ph16070961. View

Zhou X, Weng W, Chen B, Feng W, Wang W, Nie W . Mesoporous silica nanoparticles/gelatin porous composite scaffolds with localized and sustained release of vancomycin for treatment of infected bone defects. J Mater Chem B. 2020; 6(5):740-752. DOI: 10.1039/c7tb01246b. View

Alvarez E, Gonzalez B, Lozano D, Doadrio A, Colilla M, Izquierdo-Barba I . Nanoantibiotics Based in Mesoporous Silica Nanoparticles: New Formulations for Bacterial Infection Treatment. Pharmaceutics. 2021; 13(12). PMC: 8703556. DOI: 10.3390/pharmaceutics13122033. View

Haddad Kashani H, Schmelcher M, Sabzalipoor H, Hosseini E, Moniri R . Recombinant Endolysins as Potential Therapeutics against Antibiotic-Resistant Staphylococcus aureus: Current Status of Research and Novel Delivery Strategies. Clin Microbiol Rev. 2017; 31(1). PMC: 5740972. DOI: 10.1128/CMR.00071-17. View

Pan L, He Q, Liu J, Chen Y, Ma M, Zhang L . Nuclear-targeted drug delivery of TAT peptide-conjugated monodisperse mesoporous silica nanoparticles. J Am Chem Soc. 2012; 134(13):5722-5. DOI: 10.1021/ja211035w. View

Xu T, Yan X, Kang A, Yang L, Li X, Tian Y . Development of Membrane-Targeting Fluorescent 2-Phenyl-1-phenanthro[9,10-]imidazole-Antimicrobial Peptide Mimic Conjugates against Methicillin-Resistant . J Med Chem. 2024; 67(11):9302-9317. DOI: 10.1021/acs.jmedchem.4c00436. View

Wang D, van der Mei H, Ren Y, Busscher H, Shi L . Lipid-Based Antimicrobial Delivery-Systems for the Treatment of Bacterial Infections. Front Chem. 2020; 7:872. PMC: 6965326. DOI: 10.3389/fchem.2019.00872. View

Hulten K, Mason E, Lamberth L, Forbes A, Revell P, Kaplan S . Analysis of Invasive Community-Acquired Methicillin-Susceptible Staphylococcus aureus Infections During a Period of Declining Community Acquired Methicillin-Resistant Staphylococcus aureus Infections at a Large Children's Hospital. Pediatr Infect Dis J. 2017; 37(3):235-241. DOI: 10.1097/INF.0000000000001753. View

10.

Kurczewska J, Sawicka P, Ratajczak M, Gajecka M, Schroeder G . Vancomycin-modified silica: Synthesis, controlled release and biological activity of the drug. Int J Pharm. 2015; 486(1-2):226-31. DOI: 10.1016/j.ijpharm.2015.04.005. View

11.

Popat A, Budi Hartono S, Stahr F, Liu J, Qiao S, Lu G . Mesoporous silica nanoparticles for bioadsorption, enzyme immobilisation, and delivery carriers. Nanoscale. 2011; 3(7):2801-18. DOI: 10.1039/c1nr10224a. View

12.

Qi G, Li L, Yu F, Wang H . Vancomycin-modified mesoporous silica nanoparticles for selective recognition and killing of pathogenic gram-positive bacteria over macrophage-like cells. ACS Appl Mater Interfaces. 2013; 5(21):10874-81. DOI: 10.1021/am403940d. View

13.

Akbari M, Rezayan A, Rastegar H, Alebouyeh M, Yahyaei M . Design and synthesis of vancomycin-functionalized ZnFe O nanoparticles as an effective antibacterial agent against methicillin-resistant Staphylococcus aureus. Drug Dev Res. 2024; 85(1):e22148. DOI: 10.1002/ddr.22148. View

14.

Li L, Wang H . Enzyme-coated mesoporous silica nanoparticles as efficient antibacterial agents in vivo. Adv Healthc Mater. 2013; 2(10):1351-60. DOI: 10.1002/adhm.201300051. View

15.

Nasaj M, Farmany A, Shokoohizadeh L, Jalilian F, Mahjoub R, Roshanaei G . Vancomycin and nisin-modified magnetic FeO@SiO nanostructures coated with chitosan to enhance antibacterial efficiency against methicillin resistant Staphylococcus aureus (MRSA) infection in a murine superficial wound model. BMC Chem. 2024; 18(1):43. PMC: 10893753. DOI: 10.1186/s13065-024-01129-y. View

16.

Zeng M, Shu Y, Parra-Robert M, Desai D, Zhou H, Li Q . Scalable synthesis of multicomponent multifunctional inorganic core@mesoporous silica shell nanocomposites. Mater Sci Eng C Mater Biol Appl. 2021; 128:112272. DOI: 10.1016/j.msec.2021.112272. View

17.

Gupta P, Rajput M, Oza T, Trivedi U, Sanghvi G . Eminence of Microbial Products in Cosmetic Industry. Nat Prod Bioprospect. 2019; 9(4):267-278. PMC: 6646485. DOI: 10.1007/s13659-019-0215-0. View

18.

Zhuang J, Yu Y, Lu R . Mesoporous silica nanoparticles as carrier to overcome bacterial drug resistant barriers. Int J Pharm. 2022; 631:122529. DOI: 10.1016/j.ijpharm.2022.122529. View

19.

Natan M, Banin E . From Nano to Micro: using nanotechnology to combat microorganisms and their multidrug resistance. FEMS Microbiol Rev. 2017; 41(3):302-322. DOI: 10.1093/femsre/fux003. View

20.

Konar M, Mathew A, Dasgupta S . Effect of Silica Nanoparticles on the Amyloid Fibrillation of Lysozyme. ACS Omega. 2019; 4(1):1015-1026. PMC: 6648903. DOI: 10.1021/acsomega.8b03169. View